On January 19, 2016, Curaxis Pharmaceutical Corporation went out of business as per its Chapter 7 liquidation filing under bankruptcy. Curaxis Pharmaceutical Corporation, a development stage specialty pharmaceutical company, focuses on developing a hormone drug product candidate for the treatment of Alzheimer’s disease and multiple cancers. Its therapeutic platform is based on the hypothesis that various diseases of aging might be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis, a hormonal endocrine feedback loop that controls development, reproduction, and aging in animals. The company’s clinical programs include ALADDIN I, which completed Phase II clinical trial to evaluate leuprolide acetate for the treatment of women aged 65 years or older with mild to moderate Alzheimer’s disease; ALADDIN II, which completed Phase II clinical trial to evaluate leuprolide acetate for the treatment of men aged 65 years or older with mild to moderate Alzheimer’s disease; and ALADDIN 105 that completed Phase I clinical trial to determine the safety and tolerability of VP4896 implants at various dose combinations on healthy post-menopausal women aged 45 to 70 years and men aged between 50 to 70 years. Curaxis Pharmaceutical Corporation was founded in 2001 and is based in Raleigh, North Carolina.